X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Reyvow (lasmiditan hemisuccinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.
Lead Product(s): Lasmiditan
Therapeutic Area: Neurology Product Name: Reyvow
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
Under the terms of the agreement, Ildong will license a suite of Twist’s VHH antibody libraries for a period of three years and will use the libraries to conduct research and development activities.
Lead Product(s): VHH Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Twist Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 30, 2022
Details:
A Phase 1 study on new drug candidate IDG16177 of novel oral treatment for type 2 diabetes, which is being developed by Ildong Pharmaceutical, is initiated in Germany.
Lead Product(s): IDG16177
Therapeutic Area: Endocrinology Product Name: IDG16177
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021
Details:
Under the terms of the agreement, Evotec's experts in Integrated development solutions will accelerate the development of Ildong's projects with services from Evotec's comprehensive INDiGO platform.
Lead Product(s): IDG-16177
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Evotec
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
